目的通过检测健康人及良恶性肿瘤患者外周血 T 淋巴细胞核仁形成区嗜银蛋白(Ag～NORs),探讨其与机体免疫状况的关系,研究其在肿瘤诊断和病情监测中的应用价值。方法应用细胞银染技术对体外激活的人外周血 T 淋巴细胞染色,通过 KL 型肿...目的通过检测健康人及良恶性肿瘤患者外周血 T 淋巴细胞核仁形成区嗜银蛋白(Ag～NORs),探讨其与机体免疫状况的关系,研究其在肿瘤诊断和病情监测中的应用价值。方法应用细胞银染技术对体外激活的人外周血 T 淋巴细胞染色,通过 KL 型肿瘤免疫图像分析系统检测Ag-NORs 含量(硝酸银染色酸性非组蛋白面积与细胞核面积的比值)即 IS%值。结果经统计学分析发现,健康人群中男女性的 T 淋巴细胞 Ag-NORs 的 IS%值分别为(7.77±0.61)%及(7.89±0.53)%,无显著性差异(P>0.05);良性肿瘤患者 IS%值为(7.66±0.60)%,比正常对照组(7.84±0.57)%略降低,但无显著性差异(P>0.05);恶性肿瘤患者 IS%值比正常对照组明显降低,为(4.46±0.69)%,健康人群及良性肿瘤患者与恶性肿瘤患者之间有显著性差异(P<0.05);在肺癌、胃癌、肝癌、大肠癌、乳腺癌等其他不同恶性肿瘤患者之间比较,结果分别为(4.46±0.75)%、(4.29±0.70)%、(4.62±0.69)%、(4.45±0.57)%、(4.50±0.69)%、(4.56±0.76)%,各种类型肿瘤患者间无显著性差异(P>0.05);恶性肿瘤患者不同临床时期即化疗前后 IS%值分别为(4.45±0.74)%、(3.86±0.71)%,有显著性差异(P<0.05);恶性肿瘤化疗后依据疗效不同(完全缓解、部分缓解、转移),IS%值随肿瘤病情恶化依次降低,分别为(6.57±0.47)%、(5.32±0.46)%、(3.47±0.42)%,有显著性差异。结论恶性肿瘤患者 T 细胞 Ag-NORs 值明显低于健康人群及良性肿瘤患者;外周血T淋巴细胞 Ag-NORs 检测在肿瘤诊断和病情监测等方面具有重要意义。展开更多
对77例胃粘膜活检标本进行银染,显示核仁组成区相关的嗜银蛋白(Ag-NOR),进行计数和统计分析,并对银染标本作电镜观察及能谱分析。结果表明,Ag-NOR 颗粒计数的多少,对胃肿瘤恶性程度的诊断有重要参考价值。电镜证实银染物质定位于核仁组...对77例胃粘膜活检标本进行银染,显示核仁组成区相关的嗜银蛋白(Ag-NOR),进行计数和统计分析,并对银染标本作电镜观察及能谱分析。结果表明,Ag-NOR 颗粒计数的多少,对胃肿瘤恶性程度的诊断有重要参考价值。电镜证实银染物质定位于核仁组成区,银染阳性区能谱分析显示 Ag 峰,说明银染反应具特异性.展开更多
AIM:To determine the role of interferon(IFN)with or withoutribavirin in preventing or delaying hepatocellular carcinoma(HCC)development in patients with hepatitis C virus(HCV)related cirrhosis.Data on the preventive e...AIM:To determine the role of interferon(IFN)with or withoutribavirin in preventing or delaying hepatocellular carcinoma(HCC)development in patients with hepatitis C virus(HCV)related cirrhosis.Data on the preventive effect of IFN plusribavirin treatment are lacking.METHODS:A total of 101 patients(62 males and 39 females,mean age 55.1±1.4 years)with histologically proven HCVrelated liver cirrhosis plus compatible biochemistry andultrasonography were enrolled in the study.Biochemistryand ultrasonography were performed every 6 mo.Ultrasoundguided liver biopsy was performed on all detected focallesions.Follow-up lasted for 5 years.Cellular proliferation,evaluated by measuring Ag-NOR proteins in hepatocytesnuclei,was expressed as AgNOR-Proliferative index(AgNOR-PI)(cut-off=2.5).Forty-one patients(27 males,14 females)were only followed up after the end of anyearly treatment with IFN-alpha2b(old treatment controlgroup=OTCG).Sixty naive patients were stratified accordingto sex and AgNOR-PI and then randomized in two groups:30 were treated with IFN-alpha2b+ribavirin(treatmentgroup=TG),the remaining were not treated(control group=CG).Nonresponders(NR)or relapsers in the TG receivedfurther IFN/ribavirin treatments after a 6 mo of withdrawal.RESULTS:AgNOR-PI was significantly lowered by IFN(P<0.001).HCC incidence was higher in patients withAgNOR-PI>2.5(26% vs3%,P<0.01).Two NR in the OTCG,none in the TG and 9 patients in the CG developed HCCduring follow-up.The Kaplan-Mayer survival curves showedstatistically significant differences both between OTCG andCG(P<0.004)and between TG and CG(P<0.003).CONCLUSION:IFN/ribavirin treatment associated with re-treatment courses of NR seems to produce the best resultsin terms of HCC prevention.AgNOR-PI is a useful markerof possible HCC development.展开更多
文摘对77例胃粘膜活检标本进行银染,显示核仁组成区相关的嗜银蛋白(Ag-NOR),进行计数和统计分析,并对银染标本作电镜观察及能谱分析。结果表明,Ag-NOR 颗粒计数的多少,对胃肿瘤恶性程度的诊断有重要参考价值。电镜证实银染物质定位于核仁组成区,银染阳性区能谱分析显示 Ag 峰,说明银染反应具特异性.
文摘AIM:To determine the role of interferon(IFN)with or withoutribavirin in preventing or delaying hepatocellular carcinoma(HCC)development in patients with hepatitis C virus(HCV)related cirrhosis.Data on the preventive effect of IFN plusribavirin treatment are lacking.METHODS:A total of 101 patients(62 males and 39 females,mean age 55.1±1.4 years)with histologically proven HCVrelated liver cirrhosis plus compatible biochemistry andultrasonography were enrolled in the study.Biochemistryand ultrasonography were performed every 6 mo.Ultrasoundguided liver biopsy was performed on all detected focallesions.Follow-up lasted for 5 years.Cellular proliferation,evaluated by measuring Ag-NOR proteins in hepatocytesnuclei,was expressed as AgNOR-Proliferative index(AgNOR-PI)(cut-off=2.5).Forty-one patients(27 males,14 females)were only followed up after the end of anyearly treatment with IFN-alpha2b(old treatment controlgroup=OTCG).Sixty naive patients were stratified accordingto sex and AgNOR-PI and then randomized in two groups:30 were treated with IFN-alpha2b+ribavirin(treatmentgroup=TG),the remaining were not treated(control group=CG).Nonresponders(NR)or relapsers in the TG receivedfurther IFN/ribavirin treatments after a 6 mo of withdrawal.RESULTS:AgNOR-PI was significantly lowered by IFN(P<0.001).HCC incidence was higher in patients withAgNOR-PI>2.5(26% vs3%,P<0.01).Two NR in the OTCG,none in the TG and 9 patients in the CG developed HCCduring follow-up.The Kaplan-Mayer survival curves showedstatistically significant differences both between OTCG andCG(P<0.004)and between TG and CG(P<0.003).CONCLUSION:IFN/ribavirin treatment associated with re-treatment courses of NR seems to produce the best resultsin terms of HCC prevention.AgNOR-PI is a useful markerof possible HCC development.
